Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + nivolumab for symptomatic melanoma brain metastases
2016-004614-10Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in melanoma and brain metastases, sponsored by University Hospital Tübingen. Primary endpoint: Intracranial disease control rate at 6 months. Started Jan 2017; status: terminated.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on 2016-004614-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004614-10.